Ultragenyx Pharmaceutical Inc.
UX016
GNE myopathy
Countdown
177days
Phase 1 readout · ~ Dec 31, 2026 estimated
What's at stake
Phase 1 trial results for UX016 in GNE myopathy are due ~ Dec 31, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“an externally funded Phase 1/2 study is expected to begin in the second half of 2026.”